CD274 and cancer: Thus, blocking the PD-1/PD-L1 pathway can enhance lymphocyte activity in cancer immunotherapy The combination of Mn2+ and PD-1 antibodies (“Mn immunotherapy”) has been used and it has been found that Mn immunotherapy significantly enhances the efficacy of PD-1 antibodies and reduces their dosage in a variety of tumor models.10